Myxoid liposarcoma and the mammalian target of rapamycin pathway

Research output: Contribution to journalArticlepeer-review


PURPOSE OF REVIEW: Myxoid/round cell liposarcoma (MRCL) represents about 10% of all soft-tissue sarcomas. Therapeutic options for this subgroup of tumours are limited, essentially doxorubicin-based regimens and trabectedin. Recently, the mammalian target of rapamycin (mTOR) pathway has been identified as a therapeutic target in several sarcomas. MRCLs should be included among these, as various molecular aberrations of the mTOR pathway have been recently reported. RECENT FINDINGS: PI3KCA mutations were identified in 10-20% of MRCLs. Other molecular aberrations include loss of PTEN, Akt activation and overexpression of IGF1R. Recently, two minor responses to mTOR inhibitors were reported. SUMMARY: The relatively high frequency of mTOR signalling pathway alterations in MRCL provides a preclinical rationale for considering mTOR inhibition as a potential novel therapeutic strategy warranting further investigation.

Original languageEnglish
Pages (from-to)379-383
Number of pages5
JournalCurrent Opinion in Oncology
Issue number4
Publication statusPublished - Jul 2013


  • drug therapy
  • mTOR
  • myxoid/round cell liposarcoma
  • PI3K/Akt pathway
  • soft-tissue sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Myxoid liposarcoma and the mammalian target of rapamycin pathway'. Together they form a unique fingerprint.

Cite this